Provider of therapeutic and diagnostic devices to treat
peripheral vascular and other non-coronary diseases,
) has completed its previously announced acquisition of
privately-owned Vortex Medical.
ANGIODYNAMICS (ANGO): Free Stock Analysis
BARD C R INC (BCR): Free Stock Analysis
BOSTON SCIENTIF (BSX): Free Stock Analysis
To read this article on Zacks.com click here.
As a concern which works towards innovation and production of
medical devices for vascular occlusion, Massachusetts-based
Vortex is a strategic fit for AngioDynamics' peripheral vascular
Vortex markets the patented AngioVac system which includes the
U.S. Food and Drug Administration (FDA) cleared AngioVac Cannula
and Circuit. AngioVac Cannula and Circuit are awaiting European
CE Mark approval. The system has the potential to become the gold
standard of care for the treatment of vascular occlusion.
The acquisition is expected to be dilutive to AngioDynamics'
fiscal 2013 reported earnings by 9 cents. The company expects
fiscal 2013 adjusted earnings per share in the range of 40 cents
to 42 cents.
Following the first quarter results and the expected dilutive
impact of the acquisition on earnings per share for fiscal 2013,
the Zacks Consensus Estimate for fiscal 2013 decreased 9 cents to
40 cents per share, owing to five downward estimate revisions.
The current estimate implies year-over-year decline of 6.51%.
AngioDynamics envisages incremental revenues of $1 million in
fiscal 2013. However, the company expects an approximately $5
million decrease in operating income along with a trivial impact
For fiscal 2014, the buyout will be accretive to AngioDynamics'
top as well as bottom line. The company expects the acquisition
to boost sales by $10 million in fiscal 2014 and improve adjusted
EBITDA by $5 million.
Annual net revenues of the AngioVac system could exceed $50
million within the next five years. Thus, the acquisition will
bolster revenues for AngioDynamics' peripheral vascular division
under its vascular segment which faced a tough first quarter in
fiscal 2013. The company plans to expand the AngioVac label with
a full launch expected in the fourth quarter of fiscal 2013.
The company retains 18% share in a billion dollar market which
continues to grow in the mid-to-upper single digits. However,
AngioDynamics' product lines face strong challenges from the
competitive offerings of its larger rivals such as
Boston Scientific Corporation
CR Bard Inc
AngioDynamics currently carries a Zacks #3 Rank, which translates
into a short-term Hold rating. We have a long-term 'Neutral'
recommendation on the stock.